S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC
NCT02631460
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
470
Enrollment
OTHER
Sponsor class
Conditions
NSCLC
Interventions
DRUG:
S1 80-120 mg/d
DRUG:
pemetrexed 500 mg/m2
DRUG:
carboplatin AUC=5
Sponsor
Sun Yat-sen University